Role of Belimumab for proliferative lupus nephritis patients

This study evaluated the efficacy and safety of belimumab (BEL) with standard of care (SoC) in treating proliferative lupus nephritis (LN). Patients receiving BEL+SoC showed significantly higher complete renal response (CRR) rates at 52 weeks, reduced glucocorticoid dosages, fewer adverse events, and lower organ damage. Multivariate analysis revealed that early BEL induction (within 42 days) and the absence of early eGFR improvement predicted CRR outcomes. BEL, combined with SoC, effectively controls disease activity and limits damage in treatment-resistant LN cases.

https://mu.connect2clinic.com/doctor/description/med-for-you/48a71c46-9efa-4769-9010-6d59b38edd2d